Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9126771 | 0.98 | ALDH1A1 (0.40) | ALDH1A1LMNAHSD17B10CYP2C9TSHR | |
| SCHEMBL6128464 | 0.82 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10TSHRCHRM5 | |
| SCHEMBL1114434 | 0.80 | TSHR (0.44) | ALDH1A1LMNAHSD17B10TSHRCHRM5 | |
| SCHEMBL3481452 | 0.80 | ALDH1A1 (0.42) | ALDH1A1LMNAHSD17B10TSHRCHRM5 | |
| SCHEMBL8052693 | 0.78 | CYP2C9 (0.42) | ALDH1A1CYP2C9TSHRCHRM1TBXA2R | |
| Hydrochloric Acid SCHEMBL7654212 | 0.78 | TSHR (0.42) | ALDH1A1LMNAHSD17B10TSHRCHRM5 | |
| SCHEMBL29228036 | 0.78 | CYP2C9 (0.37) | ALDH1A1CYP2C9TSHRACLYCYP2D6 | |
| SCHEMBL1267156 | 0.78 | ALDH1A1 (0.40) | ALDH1A1LMNAHSD17B10TSHRCHRM5 | |
| SCHEMBL14906812 | 0.78 | ALDH1A1 (0.40) | ALDH1A1LMNAHSD17B10TSHRCHRM5 | |
| SCHEMBL11757494 | 0.78 | ALDH1A1 (0.40) | ALDH1A1LMNAHSD17B10TSHRCHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4051680-B1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12391697-B2 | Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250243177-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20240158415-A1 | AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL INC (US) | 2024-05-16 | — | — | US | disclosed |
| US-11667651-B2 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667651-B2 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667651-B2 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| WO-2023084449-A1 | DIAMINOCYCLOPENTYLPYRIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2023-05-19 | — | — | WO | disclosed |
| US-20230025892-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230025892-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2023-01-26 | — | — | US | disclosed |
| EP-1507826-A2 | AMELIORATION OF THE DEVELOPMENT OF CATARACTS AND OTHER OPTHALMIC DISEASES | Othera Pharmaceuticals, Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20040002461-A1 | Amelioration of the development of cataracts and other ophthalmic diseases | COLBY PHARMACEUTICAL COMPANY | 2004-01-01 | — | — | US | disclosed |
| WO-2003096991-A2 | AMELIORATION OF THE DEVELOPMENT OF CATARACTS AND OTHER OPTHALMIC DISEASES | OTHERA PHARMACEUTICALS, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
| US-5349046-A | Polymerization of β-lactones under rim conditions | SHELL OIL COMPANY (US) | 1994-09-20 | — | — | US | disclosed |
| EP-0211416-B1 | NOVEL HMG-COA REDUCTASE INHIBITORS | MERCK & CO. INC. (US) | 1991-10-16 | — | — | EP | disclosed |
| US-4851436-A | ANTICHOLESTEROL AND ANTILIPEMIC AGENTS | MERCK & CO., INC. (US) | 1989-07-25 | — | — | US | disclosed |
| US-4668699-A | 6-(NAPHTHYLETHYL)TETRAHYDROPYRAN-2-ONES; ANTILIPEMIC, ANTICHOLESTEROL | MERCK & CO., INC. (US) | 1987-05-26 | — | — | US | disclosed |
| US-4665091-A | 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A, ANTICHOLESTEROL | MERCK & CO., INC. (US) | 1987-05-12 | — | — | US | disclosed |
| EP-0211416-A2 | Novel HMG-CoA reductase inhibitors | MERCK & CO. INC. (US) | 1987-02-25 | — | — | EP | disclosed |
| US-4405357-A | Herbicidal 3-isoxazolidinones and hydroxamic acids | FMC CORPORATION (US) | 1983-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158415-A1 | AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | PIP5K1B, PIP5K1A, PIP5K1C | ALDH1A1 4193/4885LMNA 4267/4885HSD17B10 3939/4885 |
| US-20230025892-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, CDK1, CDK2 | ALDH1A1 2619/4885LMNA 1417/4885HSD17B10 3067/4885 |
| US-11667651-B2 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | PIP5K1B, PIP5K1A, PIP5K1C | ALDH1A1 4132/4885LMNA 4121/4885HSD17B10 3968/4885 |
| US-20250243177-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | ALDH1A1 1325/4885LMNA 3689/4885HSD17B10 660/4885 |
| US-12391697-B2 | Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase | ABL1, CDK1, CDK2 | ALDH1A1 2619/4885LMNA 1417/4885HSD17B10 3067/4885 |
| US-20040002461-A1 | Amelioration of the development of cataracts and other ophthalmic diseases | PDE6D, PDE6H, CCR1 | ALDH1A1 310/4885LMNA 1234/4885HSD17B10 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.